<i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents
<i>Background</i>: Reversion mutations in <i>BRCA1/2</i>, resulting in restoration of the open reading frame, have been identified as a mechanism of resistance to platinum-based chemotherapy or PARP inhibition. We sought to explore the incidence of <i>BRCA1/2</i>...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/58/12/1818 |
| _version_ | 1797456414384324608 |
|---|---|
| author | Sourat Darabi David R. Braxton Joanne Xiu Benedito A. Carneiro Jeff Swensen Emmanuel S. Antonarakis Stephen V. Liu Rana R. McKay David Spetzler Wafik S. El-Deiry Michael J. Demeure |
| author_facet | Sourat Darabi David R. Braxton Joanne Xiu Benedito A. Carneiro Jeff Swensen Emmanuel S. Antonarakis Stephen V. Liu Rana R. McKay David Spetzler Wafik S. El-Deiry Michael J. Demeure |
| author_sort | Sourat Darabi |
| collection | DOAJ |
| description | <i>Background</i>: Reversion mutations in <i>BRCA1/2</i>, resulting in restoration of the open reading frame, have been identified as a mechanism of resistance to platinum-based chemotherapy or PARP inhibition. We sought to explore the incidence of <i>BRCA1/2</i> reversion mutations in different tumor types. <i>Methods</i>: We retrospectively analyzed molecular profiling results from primary and/or metastatic tumor samples submitted by multiple institutions. The samples underwent DNA and RNA sequencing at a CLIA/CAP-certified clinical lab. Reversion mutations were called only in patients whose available clinical records showed the use of PARP inhibitors or platinum agents prior to tumor profiling. <i>Results</i>: Reversion mutations were identified in 75 of 247,926 samples profiled across all tumor types. Among patients carrying pathogenic or likely pathogenic <i>BRCA1/2</i> mutations, reversion mutations in <i>BRCA1/2</i> genes were seen in ovarian cancer (OC) (30/3424), breast cancer (BC) (27/1460), endometrial cancer (4/564), pancreatic cancer (2/340), cholangiocarcinoma (2/178), prostate cancer (5/461), cervical cancer (1/117), cancer of unknown primary (1/244), bladder cancer (1/300), malignant pleural mesothelioma (1/10), and a neuroendocrine tumor of the prostate. We identified 22 reversion mutations in <i>BRCA1</i> and 8 in <i>BRCA2</i> in OC. In BC, we detected 6 reversion mutations in <i>BRCA1</i> and 21 in <i>BRCA2.</i> We compared molecular profile results of 14 high-grade serous ovarian cancers (HGSOC) with reversion mutations against 87 control HGSOC with pathogenic <i>BRCA1/2</i> mutations without reversion mutations. Tumors with reversion mutations trended to have had lower ER expression (25% vs. 64%, <i>p</i> = 0.024, q = 0.82) and higher <i>KDM6A</i> mutation rate (15% vs. 0, <i>p</i> = 0.016, q = 0.82). <i>Conclusions</i>: We present one of the largest datasets reporting reversion mutations in <i>BRCA1/2</i> genes across various tumor types. These reversion mutations were rare; this may be because some patients may not have had repeat profiling post-treatment. Repeat tumor profiling at times of treatment resistance can help inform therapy selection in the refractory disease setting. |
| first_indexed | 2024-03-09T16:07:34Z |
| format | Article |
| id | doaj.art-ba50c0656e284a5c8fe58a59c2af572c |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-09T16:07:34Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-ba50c0656e284a5c8fe58a59c2af572c2023-11-24T16:33:16ZengMDPI AGMedicina1010-660X1648-91442022-12-015812181810.3390/medicina58121818<i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum AgentsSourat Darabi0David R. Braxton1Joanne Xiu2Benedito A. Carneiro3Jeff Swensen4Emmanuel S. Antonarakis5Stephen V. Liu6Rana R. McKay7David Spetzler8Wafik S. El-Deiry9Michael J. Demeure10Hoag Family Cancer Institute, Newport Beach, CA 92663, USAHoag Family Cancer Institute, Newport Beach, CA 92663, USACaris Life Sciences, Phoenix, AZ 85040, USALegorreta Cancer Center, Brown University, Providence, RI 02912, USACaris Life Sciences, Phoenix, AZ 85040, USAUniversity of Minnesota Masonic Cancer Center, Minneapolis, MN 55455, USAGeorgetown University, Washington, DC 20057, USAUniversity of California San Diego Health, La Jolla, CA 92093, USACaris Life Sciences, Phoenix, AZ 85040, USALegorreta Cancer Center, Brown University, Providence, RI 02912, USAHoag Family Cancer Institute, Newport Beach, CA 92663, USA<i>Background</i>: Reversion mutations in <i>BRCA1/2</i>, resulting in restoration of the open reading frame, have been identified as a mechanism of resistance to platinum-based chemotherapy or PARP inhibition. We sought to explore the incidence of <i>BRCA1/2</i> reversion mutations in different tumor types. <i>Methods</i>: We retrospectively analyzed molecular profiling results from primary and/or metastatic tumor samples submitted by multiple institutions. The samples underwent DNA and RNA sequencing at a CLIA/CAP-certified clinical lab. Reversion mutations were called only in patients whose available clinical records showed the use of PARP inhibitors or platinum agents prior to tumor profiling. <i>Results</i>: Reversion mutations were identified in 75 of 247,926 samples profiled across all tumor types. Among patients carrying pathogenic or likely pathogenic <i>BRCA1/2</i> mutations, reversion mutations in <i>BRCA1/2</i> genes were seen in ovarian cancer (OC) (30/3424), breast cancer (BC) (27/1460), endometrial cancer (4/564), pancreatic cancer (2/340), cholangiocarcinoma (2/178), prostate cancer (5/461), cervical cancer (1/117), cancer of unknown primary (1/244), bladder cancer (1/300), malignant pleural mesothelioma (1/10), and a neuroendocrine tumor of the prostate. We identified 22 reversion mutations in <i>BRCA1</i> and 8 in <i>BRCA2</i> in OC. In BC, we detected 6 reversion mutations in <i>BRCA1</i> and 21 in <i>BRCA2.</i> We compared molecular profile results of 14 high-grade serous ovarian cancers (HGSOC) with reversion mutations against 87 control HGSOC with pathogenic <i>BRCA1/2</i> mutations without reversion mutations. Tumors with reversion mutations trended to have had lower ER expression (25% vs. 64%, <i>p</i> = 0.024, q = 0.82) and higher <i>KDM6A</i> mutation rate (15% vs. 0, <i>p</i> = 0.016, q = 0.82). <i>Conclusions</i>: We present one of the largest datasets reporting reversion mutations in <i>BRCA1/2</i> genes across various tumor types. These reversion mutations were rare; this may be because some patients may not have had repeat profiling post-treatment. Repeat tumor profiling at times of treatment resistance can help inform therapy selection in the refractory disease setting.https://www.mdpi.com/1648-9144/58/12/1818<i>BRCA1/2</i>reversion mutationsPARP inhibitorsresistance mechanismsplatinum-based therapy |
| spellingShingle | Sourat Darabi David R. Braxton Joanne Xiu Benedito A. Carneiro Jeff Swensen Emmanuel S. Antonarakis Stephen V. Liu Rana R. McKay David Spetzler Wafik S. El-Deiry Michael J. Demeure <i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents Medicina <i>BRCA1/2</i> reversion mutations PARP inhibitors resistance mechanisms platinum-based therapy |
| title | <i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents |
| title_full | <i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents |
| title_fullStr | <i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents |
| title_full_unstemmed | <i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents |
| title_short | <i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents |
| title_sort | i brca1 2 i reversion mutations in patients treated with poly adp ribose polymerase parp inhibitors or platinum agents |
| topic | <i>BRCA1/2</i> reversion mutations PARP inhibitors resistance mechanisms platinum-based therapy |
| url | https://www.mdpi.com/1648-9144/58/12/1818 |
| work_keys_str_mv | AT souratdarabi ibrca12ireversionmutationsinpatientstreatedwithpolyadpribosepolymeraseparpinhibitorsorplatinumagents AT davidrbraxton ibrca12ireversionmutationsinpatientstreatedwithpolyadpribosepolymeraseparpinhibitorsorplatinumagents AT joannexiu ibrca12ireversionmutationsinpatientstreatedwithpolyadpribosepolymeraseparpinhibitorsorplatinumagents AT beneditoacarneiro ibrca12ireversionmutationsinpatientstreatedwithpolyadpribosepolymeraseparpinhibitorsorplatinumagents AT jeffswensen ibrca12ireversionmutationsinpatientstreatedwithpolyadpribosepolymeraseparpinhibitorsorplatinumagents AT emmanuelsantonarakis ibrca12ireversionmutationsinpatientstreatedwithpolyadpribosepolymeraseparpinhibitorsorplatinumagents AT stephenvliu ibrca12ireversionmutationsinpatientstreatedwithpolyadpribosepolymeraseparpinhibitorsorplatinumagents AT ranarmckay ibrca12ireversionmutationsinpatientstreatedwithpolyadpribosepolymeraseparpinhibitorsorplatinumagents AT davidspetzler ibrca12ireversionmutationsinpatientstreatedwithpolyadpribosepolymeraseparpinhibitorsorplatinumagents AT wafikseldeiry ibrca12ireversionmutationsinpatientstreatedwithpolyadpribosepolymeraseparpinhibitorsorplatinumagents AT michaeljdemeure ibrca12ireversionmutationsinpatientstreatedwithpolyadpribosepolymeraseparpinhibitorsorplatinumagents |